The ministry wants the policy to simplify the licensing system to avoid duplication of efforts and ensure better coordination among different regulatory authorities
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
A list out 51 medical problems including several metabolic disorders has been brought under the duty exempted category for import for personal use.
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Lupin has received U.S. FDA approval for Mirabegron Extended-Release Tablets used for the treatment of overactive bladder.
The seizure is the biggest haul at any airport in India.
CAIT demands action against senior management of the ecommerce giant after marijuana found in a fulfillment centre.
In a post-coronavirus world, India can become a major provider of global public-goods and services like healthcare.
